Physician profile
Mary Dek
NPI 1124187984
$2,391.82
in general payments reported to CMS, 2019-2025
29 companies · $255 in 2025
The $255 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $49.39 · 2021: $534 · 2022: $493 · 2023: $393 · 2024: $383 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $596.63 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $283.33 | 2019-2025 | |
| Sanofi Pasteur INC. | $121.28 | 2019-2025 | |
| Neos Therapeutics, LP | $118.78 | 2020-2025 | Cotempla Xr-Odt |
| Kaleo, INC. | $114.96 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $104.13 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $90.76 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $87.41 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $85.61 | 2021-2024 | Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $82.36 | 2022-2024 | Flumist Quadrivalent |
| Sanofi-Aventis U.S. LLC | $77.86 | 2024 | |
| Alk-Abello, INC | $75.87 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $67.63 | 2019 | |
| Genentech USA, INC. | $58.81 | 2020-2022 | |
| Seqirus USA INC | $53.05 | 2024-2025 | Flucelvax |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $50.02 | 2019-2025 | Third Wave, Aptima |
| Corium, LLC | $45.80 | 2022 | |
| Sobi, INC | $43.47 | 2021-2023 | |
| Adlon Therapeutics L.P. | $32.52 | 2021 | |
| Shire North American Group INC | $29.42 | 2019 | |
| Glaxosmithkline, LLC. | $24.16 | 2021-2024 | Bexsero |
| Vertical Pharmaceuticals, LLC | $24.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.94 | 2021 | |
| Kyowa Kirin, INC. | $20.57 | 2023 | Crysvita |
| Acadia Pharmaceuticals INC | $16.94 | 2025 | Daybue |
| Sarepta Therapeutics, INC. | $16.93 | 2022 | |
| Biomarin Pharmaceutical INC. | $16.85 | 2023 | Voxzogo 1.2mg |
| Ars Pharmaceuticals Operations, INC. | $16.15 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $13.46 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.